Last reviewed · How we verify

Extended Release Tacrolimus Tablets

Roy D. Bloom, MD · FDA-approved active Small molecule Quality 5/100

Extended Release Tacrolimus Tablets is a Small molecule drug developed by Roy D. Bloom, MD. It is currently FDA-approved. Also known as: LCPT, Envarsus XR®.

At a glance

Generic nameExtended Release Tacrolimus Tablets
Also known asLCPT, Envarsus XR®
SponsorRoy D. Bloom, MD
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Extended Release Tacrolimus Tablets

What is Extended Release Tacrolimus Tablets?

Extended Release Tacrolimus Tablets is a Small molecule drug developed by Roy D. Bloom, MD.

Who makes Extended Release Tacrolimus Tablets?

Extended Release Tacrolimus Tablets is developed and marketed by Roy D. Bloom, MD (see full Roy D. Bloom, MD pipeline at /company/roy-d-bloom-md).

Is Extended Release Tacrolimus Tablets also known as anything else?

Extended Release Tacrolimus Tablets is also known as LCPT, Envarsus XR®.

What development phase is Extended Release Tacrolimus Tablets in?

Extended Release Tacrolimus Tablets is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing